FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914285558> ?p ?o ?g. }

• W2914285558 endingPage "372" @default.
• W2914285558 startingPage "372" @default.
• W2914285558 abstract "To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (nAMD).To report the results of the preplanned 12-month interim analysis of 2 predefined secondary efficacy end points of a randomized clinical trial.The Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL) trial was conducted in 24 sites in Australia and included 281 treatment-naive eyes from 281 participants with active choroidal neovascularization secondary to nAMD and a visual acuity letter score of 23 or greater who were recruited between April 11, 2014, and October 31, 2015. A preplanned interim analysis was performed at month 12. Best-corrected visual acuity (BCVA) assessors and the central reading center, which determined treatment intervals, were masked to treatment assignments.Participants were randomized (1:1) to receive intravitreal injections of 0.5 mg of ranibizumab or 2.0 mg of aflibercept. After receiving 3 initial monthly injections, participants entered the TE phase.Mean change in BCVA and the number of injections from baseline to month 12.Of 281 participants, 148 (52.7%) were women and the mean (SD) age was 77.7 (8.1) years. The baseline mean BCVA letter score (approximate Snellen equivalent) was 65.3 (20/50) in the ranibizumab arm and 65.1 (20/50) in the aflibercept arm. One hundred twenty-seven ranibizumab participants (90.1%) and 121 aflibercept participants (88.3%) completed month 12 with a mean (SD [Snellen equivalent]) BCVA letter score of 72.9 (15.5 [20/32]) and 70.5 (14.6 [20/40]), respectively. The mean change in BCVA letter scores from baseline to month 12 was 7.2 (95% CI, 5.5-8.9) for ranibizumab and 4.9 (95% CI, 3.1-6.6) for aflibercept (letter score difference, 2.3; 95% CI, -0.1 to 4.7; P = .06). The mean number of injections from baseline to month 12 was 9.7 in both the ranibizumab (SD, 2.8) and aflibercept (SD, 2.6) arms with a rate ratio of 1.00 (95% CI, 1.0-1.1; P = .86).Our findings suggest that neither aflibercept nor ranibizumab for nAMD are superior to the other regarding the average visual acuity gains and number of injections during 1 year in a TE regimen. Further follow-up to 2 years may determine if advantages of one over the other can be identified.Clinicaltrials.Gov identifier: NCT02130024." @default.
• W2914285558 created "2019-02-21" @default.
• W2914285558 creator A5001215128 @default.
• W2914285558 creator A5015339066 @default.
• W2914285558 creator A5019510374 @default.
• W2914285558 creator A5020965800 @default.
• W2914285558 creator A5021828240 @default.
• W2914285558 creator A5023996852 @default.
• W2914285558 creator A5051997081 @default.
• W2914285558 creator A5089359215 @default.
• W2914285558 date "2019-04-01" @default.
• W2914285558 modified "2023-10-18" @default.
• W2914285558 title "Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration" @default.
• W2914285558 cites W1500728559 @default.
• W2914285558 cites W1968189763 @default.
• W2914285558 cites W1996171994 @default.
• W2914285558 cites W2004117352 @default.
• W2914285558 cites W2030415950 @default.
• W2914285558 cites W2083043469 @default.
• W2914285558 cites W2085712747 @default.
• W2914285558 cites W2102946567 @default.
• W2914285558 cites W2107688758 @default.
• W2914285558 cites W2124415048 @default.
• W2914285558 cites W2131192872 @default.
• W2914285558 cites W2165794331 @default.
• W2914285558 cites W2171962482 @default.
• W2914285558 cites W2343042175 @default.
• W2914285558 cites W2529823218 @default.
• W2914285558 cites W2545082692 @default.
• W2914285558 cites W2586954607 @default.
• W2914285558 cites W2609316215 @default.
• W2914285558 cites W2753708825 @default.
• W2914285558 cites W4250031098 @default.
• W2914285558 cites W633153563 @default.
• W2914285558 doi "https://doi.org/10.1001/jamaophthalmol.2018.6776" @default.
• W2914285558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6459213" @default.
• W2914285558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30676617" @default.
• W2914285558 hasPublicationYear "2019" @default.
• W2914285558 type Work @default.
• W2914285558 sameAs 2914285558 @default.
• W2914285558 citedByCount "91" @default.
• W2914285558 countsByYear W29142855582019 @default.
• W2914285558 countsByYear W29142855582020 @default.
• W2914285558 countsByYear W29142855582021 @default.
• W2914285558 countsByYear W29142855582022 @default.
• W2914285558 countsByYear W29142855582023 @default.
• W2914285558 crossrefType "journal-article" @default.
• W2914285558 hasAuthorship W2914285558A5001215128 @default.
• W2914285558 hasAuthorship W2914285558A5015339066 @default.
• W2914285558 hasAuthorship W2914285558A5019510374 @default.
• W2914285558 hasAuthorship W2914285558A5020965800 @default.
• W2914285558 hasAuthorship W2914285558A5021828240 @default.
• W2914285558 hasAuthorship W2914285558A5023996852 @default.
• W2914285558 hasAuthorship W2914285558A5051997081 @default.
• W2914285558 hasAuthorship W2914285558A5089359215 @default.
• W2914285558 hasBestOaLocation W29142855581 @default.
• W2914285558 hasConcept C118487528 @default.
• W2914285558 hasConcept C141071460 @default.
• W2914285558 hasConcept C168563851 @default.
• W2914285558 hasConcept C2776403814 @default.
• W2914285558 hasConcept C2776694085 @default.
• W2914285558 hasConcept C2777802072 @default.
• W2914285558 hasConcept C2778257484 @default.
• W2914285558 hasConcept C2778749236 @default.
• W2914285558 hasConcept C2781100027 @default.
• W2914285558 hasConcept C2781359195 @default.
• W2914285558 hasConcept C2781413609 @default.
• W2914285558 hasConcept C61943457 @default.
• W2914285558 hasConcept C71924100 @default.
• W2914285558 hasConceptScore W2914285558C118487528 @default.
• W2914285558 hasConceptScore W2914285558C141071460 @default.
• W2914285558 hasConceptScore W2914285558C168563851 @default.
• W2914285558 hasConceptScore W2914285558C2776403814 @default.
• W2914285558 hasConceptScore W2914285558C2776694085 @default.
• W2914285558 hasConceptScore W2914285558C2777802072 @default.
• W2914285558 hasConceptScore W2914285558C2778257484 @default.
• W2914285558 hasConceptScore W2914285558C2778749236 @default.
• W2914285558 hasConceptScore W2914285558C2781100027 @default.
• W2914285558 hasConceptScore W2914285558C2781359195 @default.
• W2914285558 hasConceptScore W2914285558C2781413609 @default.
• W2914285558 hasConceptScore W2914285558C61943457 @default.
• W2914285558 hasConceptScore W2914285558C71924100 @default.
• W2914285558 hasIssue "4" @default.
• W2914285558 hasLocation W29142855581 @default.
• W2914285558 hasLocation W29142855582 @default.
• W2914285558 hasLocation W29142855583 @default.
• W2914285558 hasLocation W29142855584 @default.
• W2914285558 hasOpenAccess W2914285558 @default.
• W2914285558 hasPrimaryLocation W29142855581 @default.
• W2914285558 hasRelatedWork W2019435952 @default.
• W2914285558 hasRelatedWork W2145661951 @default.
• W2914285558 hasRelatedWork W2237198389 @default.
• W2914285558 hasRelatedWork W2414742053 @default.
• W2914285558 hasRelatedWork W2543869410 @default.
• W2914285558 hasRelatedWork W2737562804 @default.
• W2914285558 hasRelatedWork W2883175396 @default.
• W2914285558 hasRelatedWork W3134869781 @default.
• W2914285558 hasRelatedWork W3190612623 @default.

• next